SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI

BACKGROUND: Taking statins for a long time is associated with an increased risk of new-onset diabetes mellitus. Sodium-glucose cotransporter-2 (SGLT2) inhibitors can reduce insulin resistance and improve pancreatic β-cell function. METHODS AND RESULTS: In total, 333 non-diabetes patients with heart...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yulin, Wang, Xiaolin, Wang, Yongchao, Xu, Hao, Li, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303340/
https://www.ncbi.nlm.nih.gov/pubmed/37369993
http://dx.doi.org/10.1186/s12872-023-03353-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303340/
https://www.ncbi.nlm.nih.gov/pubmed/37369993
http://dx.doi.org/10.1186/s12872-023-03353-1

Ejemplares similares